| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
KG5 (compound 6) has an EC50 value of 0.59 μM for vascular smooth muscle cells (VSMC) and 0.54 μM for endothelial cells, respectively, which means that it reduces their viability [1]. Compound 6 does not impact S259, but it specifically prevents S338 phosphorylation[1]. With Kd of 300 and 520 nM, respectively, and Flt3 and KIT of 52 and 170 nM, respectively, KG5 (compound 6) exclusively inhibits PDGFRα and β [1]. Compound 6 (KG5; 5 μM) prevents bFGF- or VEGF-stimulated endothelial cells from phosphorylating MEK and ERK [1].
|
|---|---|
| ln Vivo |
In an orthotopic renal cell carcinoma model, KG5 (Compound 6; 100 mg/kg; oral; daily; for 26 days) therapy inhibits tumor growth [1]. Comparing KG5 (Compound 6; 50 mg/kg; intraperitoneal; twice daily) therapy to vehicle controls (mouse injection of Matrigel containing bFGF) revealed full inhibition of angiogenesis. The area under the concentration-time curve (AUC0–12h) was 14.7 μg·h/mL, T1/2 was 11.5 h, and Cmax was 3.6 μg/mL according to pharmacokinetic studies of the dosage and formulation utilized for KG5[1]. In zebrafish development, KG5 (Compound 6; 1 μM) interferes with the last stages of angiogenesis [1].
|
| Animal Protocol |
Animal/Disease Models: Male Nu/nu (nude) mice were injected with SN12C-RFP cells [1]
Doses: 100 mg/kg Route of Administration: Oral; daily; continued for 26 days Experimental Results: Prevented tumor growth in the orthotopic renal cell carcinoma model. |
| References |
| Molecular Formula |
C20H16F3N7OS
|
|---|---|
| Molecular Weight |
459.45
|
| Exact Mass |
459.109
|
| Elemental Analysis |
C, 52.28; H, 3.51; F, 12.41; N, 21.34; O, 3.48; S, 6.98
|
| CAS # |
877874-85-6
|
| PubChem CID |
53328059
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.123
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=C(NC2NC(C3C=CC(OC4C=C(N)N=C(SC)N=4)=CC=3)=NN=2)C=CC=1)(F)F
|
| InChi Key |
CMYHZFCJPORPHY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16F3N7OS/c1-32-19-26-15(24)10-16(27-19)31-14-7-5-11(6-8-14)17-28-18(30-29-17)25-13-4-2-3-12(9-13)20(21,22)23/h2-10H,1H3,(H2,24,26,27)(H2,25,28,29,30)
|
| Chemical Name |
2-methylsulfanyl-6-[4-[3-[3-(trifluoromethyl)anilino]-1H-1,2,4-triazol-5-yl]phenoxy]pyrimidin-4-amine
|
| Synonyms |
KG5; KG 5; KG-5
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~217.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1765 mL | 10.8826 mL | 21.7652 mL | |
| 5 mM | 0.4353 mL | 2.1765 mL | 4.3530 mL | |
| 10 mM | 0.2177 mL | 1.0883 mL | 2.1765 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
